Back to Search
Start Over
Eslicarbazepine acetate as a therapeutic option in a patient with carbamazepine-induced rash and HLA-A*31:01
- Source :
- Seizure. 47:81-82
- Publication Year :
- 2017
- Publisher :
- Elsevier BV, 2017.
-
Abstract
- Eslicarbazepine acetate (ESL) is an anticonvulsant drug approved for the treatment of focal epilepsies, and related to oxcarbazepine and carbamazepine (CBZ), which are also derivatives of the dibenzazepine family. ESL is contraindicated in patients with hypersensitivity reactions to CBZ.We report a patient with frontal lobe epilepsy responding to treatment with ESL without any serious adverse effects after developing a severe skin rash following treatment with CBZ. HLA testing revealed an HLA-A*31:01 haplotype, that increases the risk of CBZ-induced cutaneous reactions.This case study shows that, in clinical practice, ESL may be considered in a patient with the HLA-A*31:01 haplotype and a hypersensitivity reaction to CBZ.
- Subjects :
- Adult
medicine.medical_specialty
Pharmacogenomic Variants
Epilepsy, Frontal Lobe
medicine.medical_treatment
HLA-B15 Antigen
Pharmacology
03 medical and health sciences
Epilepsy
0302 clinical medicine
Dibenzazepines
medicine
Humans
030212 general & internal medicine
Adverse effect
Oxcarbazepine
Voltage-Gated Sodium Channel Blockers
business.industry
General Medicine
Carbamazepine
Exanthema
medicine.disease
Rash
Dermatology
Hypersensitivity reaction
Anticonvulsant
Haplotypes
Neurology
Eslicarbazepine acetate
Anticonvulsants
Female
Neurology (clinical)
medicine.symptom
business
030217 neurology & neurosurgery
medicine.drug
Subjects
Details
- ISSN :
- 10591311
- Volume :
- 47
- Database :
- OpenAIRE
- Journal :
- Seizure
- Accession number :
- edsair.doi.dedup.....c01298b72e679e95deecb3181a825fcc